Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	511-519
Number of pages	9
Journal	The British Journal of Dermatology
Volume	189
Issue number	5
DOIs	https://doi.org/10.1093/bjd/ljad191
Publication status	Published - Oct 2023

Fields of science

@article{ff6e73d9ae90413e96081cf0771f2ad7,

title = "Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial",

author = "Sabine Altrichter and Frank Siebenhaar and Hanna Bonnekoh and Tomasz Hawro and \{et al.\}",

year = "2023",

month = oct,

doi = "10.1093/bjd/ljad191",

language = "English",

volume = "189",

pages = "511--519",

journal = "The British Journal of Dermatology",

number = "5",

}

TY - JOUR

T1 - Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial

AU - Altrichter, Sabine

AU - Siebenhaar, Frank

AU - Bonnekoh, Hanna

AU - Hawro, Tomasz

AU - et al., null

PY - 2023/10

Y1 - 2023/10

UR - https://www.scopus.com/pages/publications/85164535321

U2 - 10.1093/bjd/ljad191

DO - 10.1093/bjd/ljad191

M3 - Article

VL - 189

SP - 511

EP - 519

JO - The British Journal of Dermatology

JF - The British Journal of Dermatology

IS - 5

ER -